Our data suggest that bFGF- and OIM-related APA events may be effective targets in novel targeted therapies for CAVD and a promising biomarker for CAVD prognosis and diagnosis. Here, FGF2 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.